Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | CD274 positive |
Therapy | Retifanlimab |
Indication/Tumor Type | anal canal squamous cell carcinoma |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CD274 positive | anal canal squamous cell carcinoma | predicted - sensitive | Retifanlimab | Phase II | Actionable | In a Phase II trial (POD1UM-202), Zynyz (retifanlimab) treatment resulted in an objective response rate of 13.8% (13/94, 1 complete response, 12 partial responses), a disease control rate of 48.9%, and a median progression-free survival of 7.4 mo (patients with disease control) in patients with advanced or metastatic anal canal squamous carcinoma, with a significant correlation between tumor PD-L1 (CD274) expression and overall survival (p=0.0088) (PMID: 35816951; NCT03597295). | 35816951 |
PubMed Id | Reference Title | Details |
---|---|---|
(35816951) | A phase II study of retifanlimab (INCMGA00012) in patients with squamous carcinoma of the anal canal who have progressed following platinum-based chemotherapy (POD1UM-202). | Full reference... |